Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV – Get Free Report) have received a consensus recommendation of “Buy” from the six ratings firms that are covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $14.80.
Several equities research analysts have recently issued reports on the company. RODMAN&RENSHAW raised Achieve Life Sciences to a “strong-buy” rating in a research note on Thursday, November 14th. Rodman & Renshaw assumed coverage on Achieve Life Sciences in a research note on Thursday, November 14th. They issued a “buy” rating and a $12.00 price objective for the company.
View Our Latest Report on ACHV
Achieve Life Sciences Stock Performance
Achieve Life Sciences (NASDAQ:ACHV – Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.10). During the same quarter last year, the firm posted ($0.34) earnings per share. On average, research analysts predict that Achieve Life Sciences will post -1.17 EPS for the current fiscal year.
Institutional Investors Weigh In On Achieve Life Sciences
A number of institutional investors and hedge funds have recently modified their holdings of ACHV. SG Americas Securities LLC bought a new stake in shares of Achieve Life Sciences during the 3rd quarter worth approximately $54,000. The Manufacturers Life Insurance Company bought a new stake in Achieve Life Sciences during the 2nd quarter valued at $69,000. MetLife Investment Management LLC raised its position in Achieve Life Sciences by 65.6% during the 3rd quarter. MetLife Investment Management LLC now owns 14,993 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 5,939 shares in the last quarter. Verition Fund Management LLC bought a new stake in Achieve Life Sciences during the 3rd quarter valued at $113,000. Finally, Renaissance Technologies LLC raised its position in Achieve Life Sciences by 134.2% during the 2nd quarter. Renaissance Technologies LLC now owns 25,060 shares of the biopharmaceutical company’s stock valued at $118,000 after purchasing an additional 14,360 shares in the last quarter. 33.52% of the stock is owned by institutional investors.
About Achieve Life Sciences
Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
See Also
- Five stocks we like better than Achieve Life Sciences
- The Most Important Warren Buffett Stock for Investors: His Own
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- What Are Earnings Reports?
- What Does the Future Hold for Eli Lilly?
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.